Which statement about the PT-CPMS is true?

Which statement about the PT-CPMS is true?

• A. It defines Product 2 as Evaluation
• B. It promotes linking of selection and sequencing to the exam, eval, diagnosis, and prognosis
• C. It discourages scaling
• D. It ignores environmental needs

Answer: (B)

Understanding this question hinges on how the PT-CPMS guides decision-making across the care process. The true statement is that the system promotes linking the selection and sequencing of assessments and actions to the exam, evaluation, diagnosis, and prognosis. In practice, this means every test, measure, and intervention is chosen with awareness of the patient’s presenting problem and how findings will influence understanding of the diagnosis and the likely course of recovery. This connected approach keeps the plan of care coherent from initial assessment through prognosis, guiding which steps come next and how they relate to expected outcomes. This integrated flow contrasts with thinking that a single component is just the evaluation, or that scaling and environmental considerations are separate from clinical decisions. It’s not about isolating evaluation as a standalone product, and it certainly isn’t about ignoring environmental needs or avoiding adjustments in response to patient progress. The strength of the PT-CPMS lies in keeping selection and sequencing tied to the evolving clinical picture and prognosis, so care remains focused and responsive.

Understanding this question hinges on how the PT-CPMS guides decision-making across the care process. The true statement is that the system promotes linking the selection and sequencing of assessments and actions to the exam, evaluation, diagnosis, and prognosis. In practice, this means every test, measure, and intervention is chosen with awareness of the patient’s presenting problem and how findings will influence understanding of the diagnosis and the likely course of recovery. This connected approach keeps the plan of care coherent from initial assessment through prognosis, guiding which steps come next and how they relate to expected outcomes.

This integrated flow contrasts with thinking that a single component is just the evaluation, or that scaling and environmental considerations are separate from clinical decisions. It’s not about isolating evaluation as a standalone product, and it certainly isn’t about ignoring environmental needs or avoiding adjustments in response to patient progress. The strength of the PT-CPMS lies in keeping selection and sequencing tied to the evolving clinical picture and prognosis, so care remains focused and responsive.